Cargando…
C-type Lectin Receptors for Tumor Eradication: Future Directions
Dendritic cells are key regulators in directing immune responses and therefore are under extensive research for the induction of anti-tumor responses. DCs express a large array of receptors by which they scan their surroundings for recognition and uptake of pathogens. One of the receptor-families is...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759192/ https://www.ncbi.nlm.nih.gov/pubmed/24212951 http://dx.doi.org/10.3390/cancers3033169 |
_version_ | 1782477221013749760 |
---|---|
author | Streng-Ouwehand, Ingeborg Unger, Wendy W. J. van Kooyk, Yvette |
author_facet | Streng-Ouwehand, Ingeborg Unger, Wendy W. J. van Kooyk, Yvette |
author_sort | Streng-Ouwehand, Ingeborg |
collection | PubMed |
description | Dendritic cells are key regulators in directing immune responses and therefore are under extensive research for the induction of anti-tumor responses. DCs express a large array of receptors by which they scan their surroundings for recognition and uptake of pathogens. One of the receptor-families is the C-type lectins (CLR), which bind carbohydrate structures and internalize antigens upon recognition. Intracellular routing of antigen through CLR enhances loading and presentation of antigen through MHC class I and II, inducing antigen-specific CD4(+) and CD8(+) T-cell proliferation and skewing T-helper cells. These characteristics make CLRs very interesting targets for DC-based immunotherapy. Profound research has been done on targeting specific tumor antigens to CLR using either antibodies or the natural ligands such as glycan structures. In this review we will focus on the current data showing the potency of CLR-targeting and discuss improvements that can be achieved to enhance anti-tumor activity in the near future. |
format | Online Article Text |
id | pubmed-3759192 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Molecular Diversity Preservation International (MDPI) |
record_format | MEDLINE/PubMed |
spelling | pubmed-37591922013-09-04 C-type Lectin Receptors for Tumor Eradication: Future Directions Streng-Ouwehand, Ingeborg Unger, Wendy W. J. van Kooyk, Yvette Cancers (Basel) Review Dendritic cells are key regulators in directing immune responses and therefore are under extensive research for the induction of anti-tumor responses. DCs express a large array of receptors by which they scan their surroundings for recognition and uptake of pathogens. One of the receptor-families is the C-type lectins (CLR), which bind carbohydrate structures and internalize antigens upon recognition. Intracellular routing of antigen through CLR enhances loading and presentation of antigen through MHC class I and II, inducing antigen-specific CD4(+) and CD8(+) T-cell proliferation and skewing T-helper cells. These characteristics make CLRs very interesting targets for DC-based immunotherapy. Profound research has been done on targeting specific tumor antigens to CLR using either antibodies or the natural ligands such as glycan structures. In this review we will focus on the current data showing the potency of CLR-targeting and discuss improvements that can be achieved to enhance anti-tumor activity in the near future. Molecular Diversity Preservation International (MDPI) 2011-08-08 /pmc/articles/PMC3759192/ /pubmed/24212951 http://dx.doi.org/10.3390/cancers3033169 Text en © 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Streng-Ouwehand, Ingeborg Unger, Wendy W. J. van Kooyk, Yvette C-type Lectin Receptors for Tumor Eradication: Future Directions |
title | C-type Lectin Receptors for Tumor Eradication: Future Directions |
title_full | C-type Lectin Receptors for Tumor Eradication: Future Directions |
title_fullStr | C-type Lectin Receptors for Tumor Eradication: Future Directions |
title_full_unstemmed | C-type Lectin Receptors for Tumor Eradication: Future Directions |
title_short | C-type Lectin Receptors for Tumor Eradication: Future Directions |
title_sort | c-type lectin receptors for tumor eradication: future directions |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759192/ https://www.ncbi.nlm.nih.gov/pubmed/24212951 http://dx.doi.org/10.3390/cancers3033169 |
work_keys_str_mv | AT strengouwehandingeborg ctypelectinreceptorsfortumoreradicationfuturedirections AT ungerwendywj ctypelectinreceptorsfortumoreradicationfuturedirections AT vankooykyvette ctypelectinreceptorsfortumoreradicationfuturedirections |